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Background: UK policy aims to improve cancer outcomes by promoting early diagnosis, which for many haematological
malignancies is particularly challenging as the pathways leading to diagnosis can be difficult and prolonged.
Methods: A survey about symptoms was sent to patients in England with acute leukaemia, chronic lymphocytic leukaemia (CLL),
chronic myeloid leukaemia (CML), myeloma and non-Hodgkin lymphoma (NHL). Symptoms and barriers to first help seeking were
examined for each subtype, along with the relative risk of waiting43 months’ time from symptom onset to first presentation to a
doctor, controlling for age, sex and deprivation.
Results: Of the 785 respondents, 654 (83.3%) reported symptoms; most commonly for NHL (95%) and least commonly for CLL
(67.9%). Some symptoms were frequent across diseases while others were more disease-specific. Overall, 16% of patients (n¼ 114)
waited43 months before presentation; most often in CML (24%) and least in acute leukaemia (9%). Significant risk factors for43
months to presentation were: night sweats (particularly CLL and NHL), thirst, abdominal pain/discomfort, looking pale (particularly
acute leukaemias), and extreme fatigue/tiredness (particularly CML and NHL); and not realising symptom(s) were serious.
Conclusions: These findings demonstrate important differences by subtype, which should be considered in strategies promoting
early presentation. Not realising the seriousness of some symptoms indicates a worrying lack of public awareness.
Cancer outcomes in England are poorer than European averages
and this is considered to be due, at least in part, to diseases being
identified at a late stage as a consequence of delayed diagnosis
(Richards, 2009). Promotion of early diagnosis is therefore a
central tenet of the UK Department of Health’s strategy, the
overarching aim being to align UK survival rates with the best in
Europe (Department of Health, 2011a). A range of interventions to
promote early diagnosis have been introduced in the United
Kingdom (including guidelines, targets and education campaigns)
(Department of Health, 2000; NICE, 2005). These have had a
mixed impact, however (Peacock et al, 2013; Neal et al, 2014), and
as many as a quarter of people are still diagnosed with cancer after
emergency presentation to secondary care (Elliss-Brookes et al, 2012),
a route often associated with prolonged time to diagnosis,
advanced stage disease and poorer survival (McPhail et al, 2013).
Collectively, haematological malignancies are common, being
the fourth most frequently diagnosed cancer in both males and
females in economically developed regions of the world (Jemal
et al, 2008; Westlake, 2008; Ferlay et al, 2010). Traditionally
categorised into four main groups (leukaemias, Hodgkin lympho-
mas, non-Hodgkin lymphomas (NHLs) and myeloma), these
complex cancers actually comprise 460 different subtypes, each
exhibiting different patterns of onset, progression, management
and survival (Swerdlow et al, 2008). Issues relating to early
diagnosis are particularly pertinent in these diseases as, compared
with many other cancers, the pathway leading to diagnosis can be
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difficult and prolonged. These diseases are, for example, often
associated with variable symptoms, prolonged time to help seeking,
multiple primary care consultations before referral to secondary
care, diverse referral pathways and an increased risk of being
diagnosed after emergency presentation (Allgar and Neal, 2005;
Howell et al, 2006, 2007, 2013; Department of Health, 2011b;
Elliss-Brookes et al, 2012; Lyratzopoulos et al, 2012).
Further evidence-based understanding about factors impacting
on the time taken to diagnose these cancers, and identification of
means of facilitating and ensuring prompt diagnosis is therefore of
particular importance. In 2011, a study was carried out in England,
which aimed to examine time taken for patients’ to present to a
doctor and seek help for a number of different cancers, including
several haematological malignancy subtypes (Forbes et al, 2014).
This study focused on risk factors (including symptoms and barriers
to help seeking) associated with patients’ waiting43 months before
help seeking. The current paper describes detailed findings from this
study, specifically focusing on the haematological malignancies,
presenting data on a wider range of subtypes, focusing on symptoms
that are known to be common in these diseases and examining
barriers that may be specific to these cancers.
MATERIALS AND METHODS
The patients included in this paper are a subset of people who
participated in the 2010 National Cancer Patient Experience
Survey (NCPES) (Department of Health, 2010). This survey was
distributed in England to all cancer patients (aged X16 years)
receiving care across 158 NHS Trusts as day cases or in-patients,
January to March inclusive, 2010. A total of 67 713 patients
responded (67%); and 53 104 agreed they could be re-contacted for
further research purposes, including 5925 with haematological
malignancies. This group comprised patients with acute leukaemia
(acute lymphoblastic—ICD-10 C91.0 and acute myeloid—ICD-10
C92.0), chronic lymphocytic leukaemia (CLL, ICD-10 C91.1),
chronic myeloid leukaemia (CML, ICD-10 C92.1) multiple
myeloma (ICD-10 C90) and NHL (ICD-10 C82-83).
For a number of different cancers, a further questionnaire was
then mailed to a subset of patients, examining time to presentation
and risk factors for waiting43 months before first presentation to
a doctor. In accordance with the Aarthus statement (Weller et al,
2012), this time period includes the appraisal interval, which is
when the first symptoms or bodily changes are noticed by the
patient, and the help seeking interval, which is the time taken to
interpret the symptoms and/or changes and seek help. A time
period of 43 months was used to indicate prolonged time to
diagnosis as this has previously been found to have clinical
importance (Richards et al, 1999). The additional questionnaire
was sent to 200 patients randomly selected from each of the
haematological disease groups listed above; and it is these findings
which are the focus of the present paper.
Detailed information about the methods used in the second
survey have already been published (Forbes et al, 2014). The survey
instrument was a self-completed questionnaire; patients were asked
to identify the symptom(s) that had caused them to see a doctor
and led to their diagnosis from a predefined list (devised with
clinical haematology experts). Patients were also asked to indicate
the duration of time that had passed between first noticing the
symptom(s) that led to diagnosis and presenting to a doctor (p4
weeks, 4 weeks to 3 months and43 months), the date of onset of
the presenting symptom(s) and the date of their first appointment
with a doctor. Finally, participants were asked to report what (if
anything) had put them off seeing a doctor. The questionnaire was
distributed between November 2011 and January 2012, and two
reminders were sent to non-responders.
Duration of symptoms was calculated based on the time that
had passed between first noticing the symptoms that led to
diagnosis and presenting to a doctor. If this information was not
available, the first symptom that had both date of symptom onset
and date of first doctor’s appointment was used. Area-based
measures of deprivation were sourced from national data, the
Index of Multiple Deprivation (IMD) being used to categorise
individuals into quintiles (one to five): quintile one being the most
affluent and quintile five the least (Public Health Observatory,
2011). Relative risks (with 95% confidence intervals) were
calculated for time to presentation of 43 months by subtype,
presenting symptoms and any reason for putting off going to the
doctor. Age, sex and deprivation category were controlled for
owing to the possibility that these might influence time to
diagnosis (Ramirez et al, 1999; Macleod et al, 2009).
The NCPES reported perceptions of NHS patient care and was
designed to improve services, so ethics approval was not sought.
All patients had, however, consented to being approached again for
further research purposes.
RESULTS
Completeness of sample and response. Of the 5925 patients with
haematological cancers who participated in the 2010 NCPES and
agreed they could be contacted again for further research, 4820
(81.4%) were alive in November 2011. As expected, the proportion
alive varied by diagnostic group, ranging from 89.3% among
patients with CML to 68.1% in those with acute leukaemia. Of the
1000 individuals sent the survey (200 from each group), a total of
785 patients (79.4%) completed and returned the questionnaire,
and there was little variation in response by diagnostic subtype
(Table 1).
Participants. Patients were diagnosed at various time intervals
prior to participation in the NCPES in 2010. All patients with CLL,
myeloma and NHL were diagnosed in the year before the survey,
along with 90% of patients with acute leukaemia and 36% with
CML. Ten percent of patients with acute leukaemia and 44% with
CML were diagnosed 1–5 years before the survey; and 20% with
CML were diagnosed 45 years before.
The average age of participants was 58 years (range 14–84), and
those with acute leukaemia and CML were younger than the
remaining groups (53 years, range 14–80 and 52 years, range 22–
80, respectively). The vast majority of participants (95.4%) were of
white ethnic origin and a larger proportion were from IMD
quintile one (25.8%) than quintile five (13%).
Table 1. Proportion of patients with haematological
malignancies who took part in the 2010 NCPES (n¼5925)
who were alive in November 2011 and responded to the
second survey
Patents alive
in November
2011
Responded to
survey (n¼200
per subtype)
ICD-10 Cancer type N (%) N (%)
C92.1 Chronic myeloid
leukaemia (CML)
218 (89.3) 159 (79.5)
C82-83 Non-Hodgkin
lymphoma (NHL)
1730 (87.5) 161 (80.9)
C91.1 Chronic lymphocytic
leukaemia (CLL)
700 (82.1) 161 (80.5)
C90 Myeloma 1695 (78.8) 150 (76.1)
C91.0, C92.0 Acute leukaemia 477 (68.1) 154 (80.2)
Total 4820 (81.4) 785 (79.4)
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What were the symptoms that led to a diagnosis of cancer? Of the
785 patients who returned a questionnaire, 654 reported at least one
symptom (83.3%) (Table 2). Presence or absence of symptoms
varied by diagnostic group; patients with NHL were most likely to
report symptoms (95%), followed by those with acute leukaemia
(91.6%), CML (83.2%), myeloma (78.7%) and CLL (67.9%).
Similarities and differences in symptoms were identified between
disease subtypes. Across all diagnoses, systemic symptoms were
most common (particularly extreme fatigue/tiredness, unusual
sweating at night, unexpected weight-loss and pallor), followed by
pain, chest problems, lymphadenopathy and bleeding. Looking more
specifically within the systemic symptoms, extreme fatigue/tiredness
was particularly apparent among patients with acute leukaemia
(70.9%) and CML (61.2%), and unusual night sweats was most
common in patients with CML (39.6%) and CLL (35.2%).
As expected, symptoms became increasingly disease specific
beyond this: pallor and bruising/bleeding was most commonly
associated with the acute leukaemias; abnormal lumps were the
most common symptom in CLL and NHL, along with abdominal
discomfort; and bone pain/discomfort was the most frequent
symptom of myeloma. Although pain was the most common
symptom reported for myeloma (77.1%), it was also frequently
reported in other diseases, including CML (49.3%), NHL (30.1%),
acute leukaemia (29.1%) and CLL (20.4%). A plethora of additional
symptoms were noted, including unusual itching, fever and thirst.
What put you off going to the doctor? Of the 654 patients with
symptoms, 380 (58.1%) reported a reason for putting off going to
the doctor (Table 3), and there was marked variation by diagnostic
group. Patients with CML were most likely to report reasons
(90.3%), followed by acute leukaemia (68.1%), NHL (47.7%),
myeloma (43.2%) and CLL (36.1%). Overall, a third of patients
with symptoms (218/654) said they did not seek medical help earlier
because they did not realise their symptoms were serious, most
commonly patients with CML (47%) and acute leukaemia (39.7%).
Of patients who said they had not realised that their symptoms
were serious, the most commonly reported problems were fatigue,
bleeding and shortness of breath in acute leukaemia; fatigue, lump
and shortness of breath in CLL; fatigue, night sweats and weight
loss in CML; bone pain and fatigue in myeloma; and fatigue, lump
and shortness of breath in NHL.
How long was it from noticing symptoms to first seeing a
doctor? Of patients reporting at least one symptom, 91%
(n¼ 597) had data available on duration of symptoms, and
this ranged from 81% in CLL to 95% in both NHL and CML.
Overall, 16% (n¼ 104) of patients waited 43 months before
Table 2. Symptomsa reported by 654 patients with at least one symptom, by diagnosis
Total Acute leukaemiab CLL CML Myeloma NHL
Total patients 785 (100) 154 (100) 159 (100) 161 (100) 150 (100) 161 (100)
Total patients with symptoms 654 (83.3) 141 (91.6) 108 (67.9) 134 (83.2) 118 (78.7) 153 (95.0)
Systemic symptomsc 404 (61.2) 112 (79.4) 67 (62.0) 102 (76.1) 62 (52.5) 61 (39.9)
Extreme fatigue or tiredness 332 (50.8) 100 (70.9) 52 (48.1) 82 (61.2) 51 (43.2) 47 (30.7)
Unusually pale 96 (14.7) 45 (31.9) 17 (15.7) 19 (14.2) 10 (8.5) 5 (3.3)
Unusual sweating at night 154 (23.5) 26 (18.4) 38 (35.2) 53 (39.6) 12 (10.2) 25 (16.3)
Unexpected weight loss 125 (19.1) 18 (12.8) 20 (18.5) 43 (32.1) 20 (16.9) 24 (15.7)
Nausea 5 (0.8) 1 (0.7) 1 (0.9) 0 (0.0) 2 (1.7) 1 (0.7)
Faint or dizzy 8 (1.2) 0 (0.0) 3 (2.8) 2 (1.5) 0 (0.0) 3 (2.0)
Loss of appetite 2 (0.3) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7)
Pain symptomsc 266 (40.7) 41 (29.1) 22 (20.4) 66 (49.3) 91 (77.1) 46 (30.1)
Pain or discomfort in bones 181 (27.7) 34 (24.1) 14 (13.0) 30 (22.4) 87 (73.7) 16 (10.5)
Pain or discomfort in tummy 108 (16.5) 17 (12.1) 9 (8.3) 41 (30.6) 8 (6.8) 33 (21.6)
Other pain 11 (1.7) 1 (0.7) 2 (1.9) 6 (4.5) 0 (0.0) 2 (1.3)
Chest symptomsc 232 (35.5) 76 (53.9) 46 (42.6) 49 (36.6) 26 (22.0) 35 (22.9)
Shortness of breath 173 (26.5) 56 (39.7) 37 (34.3) 31 (23.1) 22 (18.6) 27 (17.6)
Lots of coughs and colds 99 (15.1) 29 (20.6) 22 (20.4) 24 (17.9) 6 (5.1) 18 (11.8)
Sore throat 9 (1.4) 6 (4.3) 1 (0.9) 0 (0.0) 0 (0.0) 2 (1.3)
Lumpc 160 (24.5) 5 (3.5) 57 (52.8) 8 (6.0) 5 (4.2) 85 (55.6)
Lump in neck, groin or armpit 139 (21.3) 4 (2.8) 56 (51.9) 1 (0.7) 0 (0.0) 78 (51.0)
Lump/swelling in tummy 10 (1.5) 0 (0.0) 1 (0.9) 6 (4.5) 2 (1.7) 1 (0.7)
Other lump 14 (2.1) 1 (0.7) 0 (0.0) 2 (1.5) 3 (2.5) 8 (5.2)
Bleeding symptomsc 126 (19.3) 51 (36.2) 16 (14.8) 35 (26.1) 15 (12.7) 9 (5.9)
Unusual bruising, rash/red spots 96 (14.7) 42 (29.8) 12 (11.1) 26 (19.4) 9 (7.6) 7 (4.6)
Unusual bleeding 49 (7.5) 22 (15.6) 4 (3.7) 13 (9.7) 8 (6.8) 2 (1.3)
Black stool 3 (0.5) 0 (0.0) 1 (0.9) 2 (1.5) 0 (0.0) 0 (0.0)
Other symptomsc
Fever 34 (5.2) 15 (10.6) 2 (1.9) 11 (8.2) 1 (0.8) 5 (3.3)
Skin unusually itchy 51 (7.8) 14 (9.9) 12 (11.1) 11 (8.2) 4 (3.4) 10 (6.5)
Unusually thirsty 33 (5.0) 5 (3.5) 7 (6.5) 9 (6.7) 6 (5.1) 6 (3.9)
Skin went yellow 14 (2.1) 6 (4.3) 4 (3.7) 0 (0.0) 2 (1.7) 2 (1.3)
Headache 9 (1.4) 4 (2.8) 0 (0.0) 2 (1.5) 1 (0.8) 2 (1.3)
Oral symptoms 3 (0.5) 2 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7)
Swollen leg 11 (1.7) 1 (0.7) 2 (1.9) 2 (1.5) 1 (0.8) 5 (3.3)
Visual problems 4 (0.6) 1 (0.7) 0 (0.0) 3 (2.2) 0 (0.0) 0 (0.0)
Bowel symptoms 11 (1.7) 0 (0.0) 1 (0.9) 1 (0.7) 2 (1.7) 7 (4.6)
Abbreviations: CLL¼ chronic lymphocytic leukaemia; CML¼ chronic myeloid leukaemia; NHL¼non-Hodgkin lymphoma. Values are reported as N (%).
a
Patients could report multiple symptoms.
b
Acute leukaemia—lymphoblastic and myeloid.
c
Calculated as a proportion of the total patients with symptoms.
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going to see a doctor. Patients with CML were most likely to report
this (n¼ 32, 24%), followed by CLL (n¼ 19, 17%), NHL (n¼ 26,
17%), myeloma (n¼ 18, 15%) and acute leukaemia (n¼ 9, 6%).
Risk factors for waiting 43 months before presentation. With
respect to symptom types across all diseases, the risk of waiting43
months to first presentation for help seeking was significantly
increased among those with unusual sweating at night, thirst, pain
or discomfort in the tummy, pallor, extreme fatigue/tiredness; and
these findings remained after adjusting for age, sex and deprivation
(Table 4). Patients who did not think their symptom(s) were
serious (n¼ 51/210, 24.3%) were more likely to put off going to the
doctor for 43 months (RR (adjusted) 1.84, 95% CI 1.24–2.67).
DISCUSSION
Waiting 43 months before symptomatic presentation to a doctor
occurred across the haematological malignancies included in this
survey. This varied considerably by subtype, however, being
relatively common in CML (24% of patients) and less so in the
acute leukaemias (10% of patients). Some symptoms were frequent
across all diseases, particularly those that were systemic, such as
fatigue. Other symptoms, however, were more specific to
individual diseases, including pallor and bruising/bleeding in the
acute leukaemias, abnormal lumps in CLL and NHL and bone pain
in myeloma. The risk factors for waiting 43 months before
seeking help varied by disease and symptom type, with many
patients reporting that this occurred because they did not realise
their symptoms were serious.
Few studies have examined symptoms prior to diagnosis
of haematological malignancies. Those that have, have tended to
use differing approaches, with some including blood parameters
(e.g., anaemia), clinical signs (e.g., hepatosplenomegaly) and
complications (e.g., renal failure), or predetermining symptom
choices, while others did not. Studies examining time intervals
preceding diagnosis are associated with similar inconsistencies,
for example, in definitions of the time periods examined, the
methods used and the way in which results are presented (Weller
et al, 2012).
Table 3. Frequency of reported barriers to seeking help from the doctor
Total Acute leukaemiaa CLL CML Myeloma NHL
Total patients 785 (100) 154 (100) 159 (100) 161 (100) 150 (100) 161 (100)
Total with symptoms 654 (83.3) 141 (91.6) 108 (67.9) 134 (83.2) 118 (78.7) 153 (95.0)
Total with symptoms reporting reasons for putting off going to doctor 380 (58.1) 96 (68.1) 39 (36.1) 121 (90.3) 51 (43.2) 73 (47.7)
Barrierb,c
Did not realise symptom was serious 218 (33.3) 56 (39.7) 28 (25.9) 63 (47.0) 30 (25.4) 41 (26.8)
Worried about wasting doctor’s time 43 (6.6) 17 (12.0) 3 (2.8) 10 (7.4) 4 (3.4) 9 (5.9)
Too many other things to worry about 28 (4.3) 5 (3.5) 2 (1.9) 12 (8.9) 6 (5.1) 3 (2.0)
Too busy to go to doctor 26 (4.0) 5 (3.5) 1 (0.9) 15 (11.2) 3 (2.5) 2 (1.3)
Worried what doctor might find 26 (4.0) 1 (0.7) 0 (0.0) 15 (11.2) 4 (3.4) 6 (3.9)
Difficult to make appointment 16 (2.4) 6 (4.3) 2 (1.9) 2 (1.4) 1 (0.8) 5 (3.3)
Doctor difficult to talk to 14 (2.1) 3 (2.1) 3 (2.8) 2 (1.4) 2 (1.7) 4 (2.6)
Otherd 9 (1.4) 3 (2.1) 0 (0.0) 2 (1.4) 1 (0.8) 3 (2.0)
Abbreviations: CLL¼ chronic lymphocytic leukaemia; CML¼ chronic myeloid leukaemia; NHL¼non-Hodgkin lymphoma. Values are reported as N (%).
a
Acute leukaemia: lymphoblastic and myeloid.
b
Categories are based on those validated in the Awareness and Beliefs about Cancer measure (Simon et al, 2012) and the Cancer Research UK Cancer Awareness Measure (Stubbings et al,
2009).
c
Percentages calculated as a proportion of the total patients with symptoms.
d
Others: did not feel confident talking about symptoms with doctor (n¼ 6); too embarrassed to see doctor (n¼ 2); difficult to arrange transport (n¼ 1).
Table 4. Risk factors and time to presentation: patients waiting 43 months before presentation compared with those who did
not
Relative risk for waiting 43 months before presentation
Proportions waiting 43 months
before presentation (%)
Unadjusted
Adjusted for age, gender
and IMD quintile
Symptoms
Unusually thirsty 11/31 (35.5) 2.30 (1.38 to 3.83) 2.00 (1.12 to 3.58)
Skin itchy 13/43 (30.2) 1.96 (1.20 to 3.21) 1.71 (0.93 to 3.13)
Unusual sweating at night 40/137 (29.2) 2.26 (1.60 to 3.19) 2.13 (1.45 to 3.11)
Looking unusually pale 22/87 (25.3) 1.69 (1.12 to 2.54) 1.60 (1.01 to 2.52)
Pain or discomfort in tummy 24/100 (24.0) 1.60 (1.07 to 2.39) 1.71 (1.13 to 2.57)
Unexpected weight loss 26/114 (22.8) 1.52 (1.02 to 2.25) 1.36 (0.88 to 2.10)
Extreme fatigue or tiredness 64/299 (21.4) 1.78 (1.24 to 2.55) 1.58 (1.08 to 2.31)
Bleeding symptoms 22/113 (19.5) 1.24 (0.81 to 1.89) 0.98 (0.60 to 1.61)
Shortness of breath 31/159 (19.5) 1.27 (0.87 to 1.85) 1.17 (0.77 to 1.76)
Lots of coughs and colds 16/88 (18.2) 1.13 (0.70 to 1.83) 1.04 (0.61 to 1.76)
Pain or discomfort in bones 30/167 (18.0) 1.13 (0.77 to 1.66) 0.99 (0.65 to 1.52)
Lump 25/148 (16.9) 1.04 (0.69 to 1.57) 1.07 (0.70 to 1.65)
Fever 4/29 (13.8) 0.83 (0.33 to 2.11) 0.69 (0.24 to 2.05)
Reported barriers for not going to doctor
Did not realise symptom
was serious
51/210 (24.3) 1.93 (1.37 to 2.73) 1.84 (1.24 to 2.67)
Abbreviation: IMD¼ Index of Multiple Deprivation.
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With respect to symptoms, however, our findings are compar-
able with those of a recent UK study examining self-reported
symptoms and time to diagnosis in 43000 patients with
haematological malignancies (Howell et al, 2013). This study
reported a similar pattern in the presence/absence of symptoms by
disease subtype, patients with NHL being the most likely to have
symptoms and patients with CLL the least. Further similarities
existed, for example, in the frequency with which systemic
symptoms (particularly fatigue) and pain were reported across all
diseases and also the frequency that certain symptoms were
reported by subtype (e.g., bleeding and bruising in acute leukaemia,
lymphadenopathy in lymphoma and pain in myeloma). Overlap
was also noted with findings of other studies examining CML,
myeloma and CLL (Ong et al, 1995; Kariyawasan et al, 2007; Irfan
and Bhurgri, 2009; Friese et al, 2011).
A number of recent studies have examined the positive
predictive value of symptoms of haematological malignancies
using GP records (Shephard et al, 2015a, b, c). Our findings are
again largely comparable; with lymphadenopathy, for example,
being common and strongly predictive of lymphoma. We
presented a wider range of symptoms than those in the original
paper by Forbes et al (2014) and identified those that were
significantly associated with waiting 43 months before
presentation—notably thirst, night sweats, pallor, abdominal pain
and extreme fatigue.
With respect to time to presentation, a number of studies have
examined this interval, although with various definitions and
categorisations. Findings from the largest, most recent UK study
found similar patterns to those reported here, with time to
presentation (i.e., the patient interval) being longest for CML (33.5
days), followed by myeloma (31 days) and CLL (22 days); the acute
leukaemias had shorter intervals (13–16 days), and the lymphomas
varied markedly by subtype (9–30 days; Howell et al, 2013).
Similarly, a further UK study found comparable results, though
identified non-prompt presentation at 15 days (Keeble et al, 2014).
Studies focusing solely on lymphoma showed variable average
patient intervals (Summerfield et al, 2000; Allgar and Neal, 2005;
Howell et al, 2006; Hansen et al, 2011), perhaps due to changes
over time, but also due to the inclusion of different subtypes of
lymphoma.
Strengths and weaknesses. The design and reporting system used
in the study complied largely with the Aarhus Statement, ensuring
consistency in definitions and methods and so comparability with
future research examining prediagnostic pathways (Weller et al,
2012). Symptom categories were haematology specific and
predetermined by clinical experts, thereby limiting options that
could be selected to those commonly associated with the target
diseases. Whilst this minimised the reporting of symptoms
potentially unrelated to the haematological malignancy, it may
also have inhibited the reporting of rarer or unusual symptoms,
particularly among the lymphomas, where symptoms vary
according to disease site(s).
This study differentiated between several haematological
cancers, which effectively highlighted variations between these
diseases; a characteristic often lost when subtypes are combined.
NHLs were, however, considered collectively, combining multiple
subtypes including those that are generally indolent (such as
follicular and marginal zone lymphomas) with those that are more
aggressive (such as diffuse large B-cell lymphoma). Similarly, acute
lymphoid and myeloid leukaemias were grouped together,
although patients with these cancer diseases have very different
age profiles. Consequently, it is possible that variations between
these disease categories may have been masked.
In addition, a number of subtypes were omitted from the
sampling frame, one being the Hodgkin lymphomas. Although our
previous work did not indicate that the symptoms associated with
these diseases varied substantially from other lymphomas
(Howell et al, 2013), it is possible that some differences may
exist. Furthermore, the categorisation of prolonged delay
(i.e., waiting 43 months before presentation) was identified in
the original study as a marker for all cancers combined (Forbes
et al, 2014). Use of this time point may not, therefore, be wholly
appropriate in the context of haematological malignancies.
The present study has a number of limitations that may impact
on generalisability, the first being that participants are considerably
younger and more affluent than average for these diseases
(Smith et al, 2011, 2015). Also, the sample of patients included
in our study is derived from the NCPES; and the number of ethnic
minority respondents to this survey was reported to be
substantially less than the population as a whole (Department of
Health, 2010). As a result, we cannot be sure our findings apply to
those of non-White ethnic origin. The NCPES was also directed at
people with in-patient/day-case episodes; and these patients may
have had different characteristics/experiences than those treated
wholly in the outpatient setting. Those receiving in-patient care, for
example, may have had more aggressive or complex disease or
been generally sicker than the patient population as a whole.
NCPES participants were also diagnosed at various time
intervals prior to completion of the survey that, in common with
many such studies using self-reported data, could lead to variation
in their ability to remember events in the time leading to
presentation and thus recall bias. Finally, the study targeted
patients who had taken part in the NCPES (administered in the
first quarter of 2010) who were still alive in November 2011, which
may introduce survivor bias as the experiences of these people may
be different from those of people dying before this time.
Importantly, the early deaths may comprise a greater proportion
of patients with later stage disease at diagnosis, possibly as a result
of longer time to presentation/diagnosis, as well as those with more
aggressive diseases, such as the acute leukaemias and some
lymphomas.
Interpretation and implications for practice. ‘Not realising
symptom(s) were serious’ was a clear risk factor for waiting 43
months before presentation and has been previously reported in
patients with haematological malignancies (Howell et al, 2008).
This may occur because many of the symptoms (e.g., fatigue,
lymphadenopathy and bone pain), are common in the general
population and often benign and self-limiting. Patients may justify
such symptoms: fatigue may be considered a natural consequence
of aging; lymphadenopathy may be attributed to localised infection
(if around the neck) or a hernia (if in the groin); and bone pain to
age-related ‘wear and tear’. The same may occur for other rarer
symptoms, such as genuine drenching night sweats, which might
be attributed by women to expected menopausal symptoms. This
process of ‘normalising’ symptoms has been reported in other
studies and is thought to be associated with prolonged time to help
seeking (Whitaker et al, 2014, 2015).
A further factor that may lead patients to conclude that their
symptoms are not serious, and result in them waiting longer before
seeking help, is the patients’ expectations of what cancer might be
like. For example, they may expect symptoms to be painful,
constant, associated with a feeling of ill health and gradually
becoming worse. However, a previous study of lymphoma (Howell
et al, 2008) reported that patients often experienced abnormal
lumps that were intermittent and painless and were not associated
with feelings of ill health or progression; alternatively, patients also
reported unexplained malaise, with no additional symptoms. These
symptoms led patients to believe they had self-limiting, benign
illnesses, rather than cancer. Also, despite some symptoms being
indicative of individual subtypes, these may be varied and a clear
‘symptom signature’ (such as a breast lump in breast cancer) does
not exist. There is also a lack of awareness about these diseases, and
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the range and combination of symptoms that may accompany
them, among the general public (Howell et al, 2008).
Failure to recognise symptoms of cancer has been tackled in the
past by campaigns such as Cancer Research UK’s ‘Be Clear on
Cancer’. Although this approach may be more challenging for the
diversely presenting haematological malignancies, this would be a
useful first step in raising awareness of these complex cancers. Any
such initiatives must, however, be balanced against finite resources
and the reality that many people with symptoms will not, in fact,
have cancer. Furthermore, it is important to recognise that
haematological malignancies are diagnosed using an array of
complex laboratory and clinical tests, and a simple first-line
screening procedure, such as the PSA test used to identify potential
prostate cancers, is not currently available.
The differences noted by subtype in the proportion of people
waiting 43 months before presentation are unsurprising. Those
with acute leukaemia are probably less likely to wait because onset
of this disease is typically acute, progression and debility can occur
rapidly and urgent medical intervention, often via emergency
presentation, is required. The remaining diseases are generally
more indolent in their onset and progression and ensuring early
presentation in this group is more challenging.
The importance of avoiding prolonged time to diagnosis of
haematological malignancies to ensure earlier stage of disease at
diagnosis and also to accrue survival advantages is not as clear as it
is for other cancers. It is likely that the tumour type and biology
have greater impact on outcomes for some subtypes, than time to
presentation. Acute leukaemias, for example, are usually associated
with shortest waiting time before seeking help (as identified in this
study, for the reasons stated above) but typically have poor survival
compared with other subtypes. Longer time to presentation of
indolent lymphoma, however, may have less impact on survival, as
these diseases are not typically treated at the earliest opportunity
postdiagnosis, but rather according to symptom burden. Also,
patients with indolent lymphomas, for example, are often
diagnosed with late-stage disease regardless of the time taken to
seek help; these diseases are characterised by bone marrow
involvement, which is automatically categorised at stage 4. Despite
this paradox, a definitive diagnosis is still required as early as
possible so that treatment decisions can be made that are
appropriate for the disease subtype. Furthermore, an excessive
time period prior to diagnosis may result in end-organ damage
(such as renal failure in myeloma and fractures), and the benefits of
avoiding this are obvious.
Future research. Presentation to a doctor is just one aspect of the
time taken to diagnose a haematological malignancy. The doctor
must then recognise that the presenting symptoms could indicate a
haematological malignancy and make timely and appropriate
referrals into secondary care. Further research is needed, alongside
primary care practitioners, to identify mechanisms by which
patients can be identified as early as possible, and routes to
haematology and diagnosis can be as seamless as possible.
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